The data continues to show an increase in the number of patients responding with increasing duration of response in chronic and accelerated phase patients. To date 34 patients have been enrolled in the study, and data will be presented from 25 evaluable patients: 15 in chronic phase, four in accelerated phase and six in blast phase.
The data demonstrated hematologic and cytogenetic responses in 86% of chronic phase patients on trial, complete hematologic responses (CHR) in 60% of chronic phase patients and cytogenetic responses in 20% of chronic phase patients. Hematologic responses were observed in all accelerated phase patients and in two of six blast phase patients. Two chronic phase patients have maintained their complete hematologic responses for more than 14 months.
Greg Collier, ChemGenex’s managing director and CEO, said: “We are seeing an increase in the number of patients who are responding to omacetaxine and a prolongation of response duration in chronic and accelerated phase patients. We look forward to the completion of clinical trial enrollment within the year, and to regulatory submission after that time.”